{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T05:10:02Z","timestamp":1752210602080,"version":"3.41.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04797-2","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:40:02Z","timestamp":1752208802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment"],"prefix":"10.1007","volume":"95","author":[{"given":"Yiming","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Vigil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahram","family":"Khanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Rampersad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"20","key":"4797_CR1","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/1078-0432.CCR-18-0536","volume":"24","author":"ML Amaya","year":"2018","unstructured":"Amaya ML, Pollyea DA (2018) Targeting the IDH2 pathway in acute myeloid leukemia. Clin Cancer Res 24(20):4931\u20134936. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0536","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4797_CR2","first-page":"247","volume":"16","author":"C DiNardo","year":"2018","unstructured":"DiNardo C (2018) Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation. Clin Adv Hematol Oncol 16(4):247\u2013249","journal-title":"Clin Adv Hematol Oncol"},{"issue":"8","key":"4797_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/17512433.2018.1477585","volume":"11","author":"J Dugan","year":"2018","unstructured":"Dugan J, Pollyea D (2018) Enasidenib for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol 11(8):755\u2013760. https:\/\/doi.org\/10.1080\/17512433.2018.1477585","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"4797_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553\u2013567. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.015","journal-title":"Cancer Cell"},{"issue":"6127","key":"4797_CR5","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1231677","volume":"339","author":"JA Losman","year":"2013","unstructured":"Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG Jr. (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339(6127):1621\u20131625. https:\/\/doi.org\/10.1126\/science.1231677","journal-title":"Science"},{"issue":"6","key":"4797_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722\u2013731. https:\/\/doi.org\/10.1182\/blood-2017-04-779405","journal-title":"Blood"},{"key":"4797_CR7","unstructured":"Squibb BM, JAN 10 (2024) (, IDHIFA\u00ae (enasidenib) {package insert}"},{"issue":"6","key":"4797_CR8","doi-asserted-by":"publisher","first-page":"e00436","DOI":"10.1002\/prp2.436","volume":"6","author":"Y Li","year":"2018","unstructured":"Li Y, Liu L, Gomez D, Chen J, Tong Z, Palmisano M, Zhou S (2018) Pharmacokinetics and safety of enasidenib following single oral doses in Japanese and Caucasian subjects. Pharmacol Res Perspect 6(6):e00436. https:\/\/doi.org\/10.1002\/prp2.436","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"4797_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/00498254.2018.1425511","volume":"49","author":"Z Tong","year":"2019","unstructured":"Tong Z, Atsriku C, Yerramilli U, Wang X, Li Y, Reyes J, Fan B, Yang H, Hoffmann M, Surapaneni S (2019) Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans. Xenobiotica 49(2):200\u2013210. https:\/\/doi.org\/10.1080\/00498254.2018.1425511","journal-title":"Xenobiotica"},{"issue":"7","key":"4797_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.2426","volume":"64","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Du S, Hu H, Wang X, Carayannopoulos L, Li Y (2024) Integrating full bayesian inference and student\u2019s t-Distribution method for enhanced outlier handling in caffeine population pharmacokinetics: assessing Drug-Drug interactions with enasidenib in relapsed or refractory AML and MDS patients. J Clin Pharmacol 64(7):866\u2013877. https:\/\/doi.org\/10.1002\/jcph.2426","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"4797_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jcph.2436","volume":"64","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Wang X, Ghosh A, Pu J, Carayannopoulos LN, Li Y (2024) Assessment of CYP-Mediated drug interactions for enasidenib based on a cocktail study in patients with relapse or refractory acute myeloid leukemia or myelodysplastic syndrome. J Clin Pharmacol 64(8):984\u2013992. https:\/\/doi.org\/10.1002\/jcph.2436","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4797_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/jcph.1979","volume":"62","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Wang X, Tong Z, Reyes J, Carayannopoulos L, Zhou S, Li Y (2022) Assessment of Transporter-Mediated drug interactions for enasidenib based on a cocktail study in patients with relapse or refractory acute myeloid leukemia or myelodysplastic syndrome. J Clin Pharmacol 62(4):494\u2013504. https:\/\/doi.org\/10.1002\/jcph.1979","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"4797_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.clml.2017.06.031","volume":"17","author":"J Bartoszko","year":"2017","unstructured":"Bartoszko J, Panzarella T, McNamara CJ, Lau A, Schimmer AD, Schuh AC, Sibai H, Maze D, Yee KWL, Devlin R, Gupta V (2017) Distribution and impact of comorbidities on survival and leukemic transformation in myeloproliferative Neoplasm-Associated myelofibrosis: A retrospective cohort study. Clin Lymphoma Myeloma Leuk 17(11):774\u2013781. https:\/\/doi.org\/10.1016\/j.clml.2017.06.031","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"4797_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/leu.2014.234","volume":"29","author":"LS Ostgard","year":"2015","unstructured":"Ostgard LS, Norgaard JM, Sengelov H, Severinsen M, Friis LS, Marcher CW, Dufva IH, Norgaard M (2015) Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia 29(3):548\u2013555. https:\/\/doi.org\/10.1038\/leu.2014.234","journal-title":"Leukemia"},{"issue":"8","key":"4797_CR15","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"4797_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1186\/s12885-015-1857-x","volume":"15","author":"M Mohammadi","year":"2015","unstructured":"Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE (2015) The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study. BMC Cancer 15:850. https:\/\/doi.org\/10.1186\/s12885-015-1857-x","journal-title":"BMC Cancer"},{"issue":"13","key":"4797_CR17","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-12-3214","volume":"19","author":"SI Shibata","year":"2013","unstructured":"Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O\u2019Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM (2013) Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute organ dysfunction working group study. Clin Cancer Res 19(13):3631\u20133639. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3214","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4797_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079\u20131089. https:\/\/doi.org\/10.1056\/NEJMoa1112304","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04797-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:40:05Z","timestamp":1752208805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04797-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4797"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04797-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have reviewed and concurred with the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees and hold equity ownership in Bristol Myers Squibb.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors are employees and hold equity ownership in Bristol Myers Squibb.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"74"}}